Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Strategy Inc. — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B), while Strategy Inc. trades at $155.19 (market cap $60.40B). The key difference: Strategy Inc. is far larger — about 10× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Strategy Inc. for 112 Days on average.
| IOVA | MSTR | |
|---|---|---|
Market Cap | $6.04B | $60.40B |
Volume | 14,805,993 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $14.82 | $320.29 |
52-Week Low | $1.81 | $82.31 |
Typical Hold Time | 0 Days | 112 Days |
Enterprise Value | $5.97B | $79.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MSTR stock trades at $155.91, up 1.66% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $3.85 billion in 2025 on $477.23 million in revenue, with a negative net income margin of -806.35%. Recent news highlights Bitcoin's price surge and Citigroup raising its price target to $240, though the stock has shown volatility around Bitcoin price movements.
The outlook is polarized: analyst consensus is bullish with a $253.36 price target, but fundamental risks are high due to persistent losses, negative cash flow from operations, and heavy debt. Investment opportunity hinges on Bitcoin's performance, while risks include earnings misses and financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
